View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 1, 2020updated 12 Jul 2022 11:48am

Science 37 teams up with AiCure for virtual clinical trials

Virtual clinical trials firm Science 37 has partnered with AiCure, an artificial intelligence (AI) and advanced data analytics firm, to provide virtual trials technology.

Virtual clinical trials firm Science 37 has partnered with AiCure, an artificial intelligence (AI) and advanced data analytics firm, for virtual trials technology.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The partners will initially leverage a virtual or decentralised research model to enable at-home participation in a clinical trial that will assess an experimental drug for major depressive disorder (MDD).

Science 37 will use its virtual model and own network of investigators and mobile nurses to enrol and support participants in the trial, which is designed for 150 adult patients in the US.

The company will also contribute via eConsent, eSource, ePRO and telemedicine expertise using its clinical trial platform.

This virtual approach is said to offer additional privacy for patients, who can remain at home, and better efficiency for researchers as Science 37 investigators could perform various common psychiatric assessments through telemedicine.

Science 37 CEO David Coman said: “Combining our comprehensive, integrated platform with AiCure’s unique AI technology will enable sponsors to develop even more meaningful data for their research.”

As part of the collaboration, AiCure will boost data quality and cut the time and cost of a trial by allowing the real-time monitoring of patient dosing.

The company’s platform can be used to track dosing adherence and measure digital biomarkers, such as facial and vocal expressivity, to assess depression in participants.

The AiCure platform also facilitates remote registration, training and micro-reimbursements to patients for increased participation.

It offers real-time access to patient-quality metrics, which deliver data-driven amendments to trial requirements and enhance the predictability of trial timelines.

AiCure CEO Dr Ed Ikeguchi said: “Virtual clinical trials offer a huge opportunity for both patients and sponsors by reducing the burden of having participants have to travel on-site, while also reducing the costs and duration of studies.

“Having the right tools in place can ensure patients remain engaged for the duration of a trial and help sponsors get critical and accurate data throughout.”

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena